NDA 016968 · Alcon
Miostat
Carbachol · Intraocular
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 21, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1972
Sep 28, 1972
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
167
132 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 10, 2023.
INDICATIONS AND USAGE: Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 18, 1995 Supplement 13 · Efficacy
- Sep 28, 1972 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- MIOSTAT · CARBACHOL 0.01% · SOLUTION, INTRAOCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbachol" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05135286 · 629 participants · Start Mar 15, 2022 · Primary completion Mar 13, 2025
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Chandler, Arizona; Phoenix, Arizona; Sun City, Arizona · 42 sites in all
- Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05270863 · 182 participants · Start Mar 30, 2022 · Primary completion Mar 17, 2023
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Glendale, California; Rancho Cordova, California; Jacksonville, Florida · 15 sites in all
- Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia PatientsPivotal-lookingRecruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06948357 · 119 participants (planned) · Start Mar 24, 2025 · Primary completion Sep 30, 2025
Drug: BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo · For: Presbyopia
Sites: Wenzhou, China
- Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-HCR21 and IY-MICStatus unknown
Il-Yang Pharm. Co., Ltd.Industry
NCT06471868 · 60 participants · Start Jun 10, 2024 · Primary completion Jun 25, 2024
Drug: IY-HCR21; IY-MIC · For: Pharmacokinetics
Sites: Seoul, South Korea
Visus TherapeuticsAcademic, hospital or other
NCT04774237 · 18 participants · Start Mar 24, 2021 · Primary completion Oct 19, 2021
Drug: BRIMOCHOL™; BRIMOCHOL™ F and 1 more · For: Presbyopia
Sites: Glendale, California; Newport Beach, California; Memphis, Tennessee
- Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine PatientsCompleted
Danish Headache CenterAcademic, hospital or other
NCT00564408 · 12 participants (planned) · Start Aug 2007 · Primary completion Oct 2008
Drug: Carbachol · For: Headache
Sites: Glostrup Municipality, Denmark
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use35
- abdominal discomfort33
- drug abuse32
- lower respiratory tract infection32
- product dose omission issue32
- amyloid arthropathy31
- arthropathy31
- intentional product misuse31
- obesity31
- pulmonary pain31
- rash31
- drug dependence30
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 10 |
| 2008 | 1 |
| 2009 | 8 |
| 2010 | 13 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 15 |
| 2022 | 11 |
| 2023 | 1 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 11 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of diclofenac sodium solution in reducing discomfort after cataract surgery.
Fry LL · J Cataract Refract Surg 1995 · Clinical Trial, Comparative Study
- Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine Gel, and Miostat.
Fry LL · J Cataract Refract Surg 1992 · Clinical Trial, Comparative Study
- Improved Presbyopic Vision With Miotics.
Abdelkader A · Eye Contact Lens 2015 · Randomized Controlled Trial
- Mitochondria are involved in bronchial smooth muscle remodeling in severe preschool wheezers.
Beaufils F, Esteves P, Enaud R, et al. · J Allergy Clin Immunol 2021 · Clinical Trial, Research Support, Non-U.S. Gov't
- Preserved endothelium-dependent vasodilatation in patients with essential hypertension.
Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. · N Engl J Med 1994 · Clinical Trial, Research Support, Non-U.S. Gov't
- The cholinomimetic agent carbachol induces headache in healthy subjects.
Schytz HW, Wienecke T, Oturai PS, et al. · Cephalalgia 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Alcon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.